List of Excipients in API PONESIMOD
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing PONESIMOD
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc | PONVORY | ponesimod | 43068-620 | CELLULOSE, MICROCRYSTALLINE | 2032-05-06 |
| Vanda Pharmaceuticals Inc | PONVORY | ponesimod | 43068-620 | CROSCARMELLOSE SODIUM | 2032-05-06 |
| Vanda Pharmaceuticals Inc | PONVORY | ponesimod | 43068-620 | FERRIC OXIDE YELLOW | 2032-05-06 |
| Vanda Pharmaceuticals Inc | PONVORY | ponesimod | 43068-620 | HYPROMELLOSE 2910 | 2032-05-06 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for PONESIMOD
Excipient focus: CELLULOSE, MICROCRYSTALLINE
PONESIMOD drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
PONESIMOD drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
PONESIMOD drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
PONESIMOD drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
PONESIMOD drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
PONESIMOD drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
PONESIMOD drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
PONESIMOD drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
PONESIMOD drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
PONESIMOD drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
PONESIMOD drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
PONESIMOD drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
PONESIMOD drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Vanda Pharmaceuticals Inc | ponesimod | 43068-620 |
| Janssen Pharmaceuticals Inc | ponesimod | 50458-720 |
| >Company | >Ingredient | >NDC |
PONESIMOD drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch